Investigation Report on Chinese Clopidogrel Market 2021-2025
Request Sample
Pre-order Enquiry
Request Customization
Check Discounts
Clopidogrel is a medication that inhibits platelet aggregation and is mainly used to prevent atherosclerotic thrombosis. The original drug, Plavix, is developed by Sanofi. It enters the Chinese market in 2001. In addition to Sanofi, the other main manufacturers of Clopidogrel in the Chinese market are Salubris Pharmaceuticals, Lepu Pharmaceutical, and CSPC Ouyi Pharmaceutical.
According to Researcher’s market research, the sales revenue of Clopidogrel in China has been decreasing since 2018, the sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020. The decrease in sales is mainly due to the impact of centralized procurement and the appearance of alternative drugs. Nevertheless, as the antithrombotic market keeps expanding, Clopidogrel will still have considerable annual sales in the short term. In addition, the price of Clopidogrel has been greatly reduced because of centralized procurement. Thus, some people may be more willing to choose Clopidogrel instead of other biosimilar drugs. Researcher concludes that as the epidemic situation improves, Clopidogrel sales in China is expected to have a restorative growth, and it will also become more stable from 2022 to 2025.
Topics Covered:
-The impact of COVID-19 on China's Clopidogrel market
- Sales value and volume of China's Clopidogrel 2016-2020
- Competitive landscape of China's Clopidogrel market
- Prices of Clopidogrel in China
- Prices of Clopidogrel in China by regions and manufacturers
- Analysis on factors affecting the development of China's Clopidogrel market
- Prospect of China's Clopidogrel market from 2021 to 2025
According to Researcher’s market research, the sales revenue of Clopidogrel in China has been decreasing since 2018, the sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020. The decrease in sales is mainly due to the impact of centralized procurement and the appearance of alternative drugs. Nevertheless, as the antithrombotic market keeps expanding, Clopidogrel will still have considerable annual sales in the short term. In addition, the price of Clopidogrel has been greatly reduced because of centralized procurement. Thus, some people may be more willing to choose Clopidogrel instead of other biosimilar drugs. Researcher concludes that as the epidemic situation improves, Clopidogrel sales in China is expected to have a restorative growth, and it will also become more stable from 2022 to 2025.
Topics Covered:
-The impact of COVID-19 on China's Clopidogrel market
- Sales value and volume of China's Clopidogrel 2016-2020
- Competitive landscape of China's Clopidogrel market
- Prices of Clopidogrel in China
- Prices of Clopidogrel in China by regions and manufacturers
- Analysis on factors affecting the development of China's Clopidogrel market
- Prospect of China's Clopidogrel market from 2021 to 2025
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Details
CRI-18084448
23-Apr-2021
50
23-Apr-2021
50
License
